Kyverna Therapeutics (KYTX) stock

Cell therapies , market cap $285M

Cell therapies for autoimmune diseases

Worth $285M

$5.08

-1.74%

As of Tuesday's close · Live for Pro members at the open

Why is KYTX down?

Down 36% in 3 months while the S&P 500 fell 2%.

Its share count rose 40.9% in a year, so each share is a smaller slice of the company.

Sources: Price history, Nov 9, 2026; Quarterly reports, Jun 30, 2026; Latest balance sheet, Aug 11, 2026

−2Long-term trend below a falling 200-day average, down over one year

Tell me next time KYTX moves

Free account, no card. An optional alert when KYTX moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →1 more reason why KYTX is down, from its filings, with the other side and the timeline, for Pro members.

Quality Score

-6

Poor

In its industry

#235of 281

Biotech

Checks firing

3of 14

Transition

From 52-week high

-62.8%

under its best in a year

KYTX's Quality Score rose 1 point on Tue, Nov 10, to -6. Trading was quieter than usual (2 chart checks started).

Follow KYTX's trial news. Pro members can get an alert when Kyverna Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when KYTX files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…PMS development strategy by early 2027, as well as additional data from the Stanford Phase 1 IIT in Q4 2026…”Trial data · SEC filing · Aug 11

Key facts on KYTX

Key facts on KYTX
Holding it back	40.9% more shares than a year ago
Latest filing	8-K, Sep 24 Issued a release: "Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis"

1 more reason behind KYTX's -6, free with an account →4 more reasons behind KYTX's -6, for Pro members.

KYTX in the news

ReportExpected to report tomorrow, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, -2.2% on average. Past reports ›

What's next

Thu Nov 19: Jefferies 17th Annual London Global…Investor conference · date confirmed.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

KYTX catalysts

Coming up

After its last 4 reports it closed -2.2% on average, higher 2 of 4 times.

3 more coming up, with sizes and sources, for Pro members.

What's next for KYTX, and how long its cash lasts

Next step the company has named

Q4 2026“Kyverna expects to provide an update on its PMS development strategy by early 2027, as well as additional data from the Stanford Phase 1 IIT in Q4 2026.”Trial data · SEC filing · Aug 11

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisPhase 2/3 · Recruiting · 66 people · main data estimated Sep 2027 · NCT06193889

1 more trial, 2 more milestones and 41 filings, for Pro members.

Cash runway

The company says its cash lasts into 2028 (8-K, Aug 11).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Mar 26, 2026)
At-the-market share sales program (424B5, filed Apr 2, 2026)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

Director Beth C Seidenberg bought 133,333 shares on Dec 18, 2025.

From Form 4: open-market buys and sales only.

Get an alert when Warner Biddle buys or sells

For Pro members: every trade, and Warner Biddle’s 17 filings and quotes.

Get an alert when KYTX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How KYTX ranks in Biotech

KYTX is #235 of 281 by Quality Score.

How KYTX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	KURAKura Oncology		Open for its score
	KYMRKymera Therapeutics		Open for its score
	LCTXLineage Cell Therapeutics		Open for its score
	LEGNLegend Biotech		Open for its score
235	KYTXKyverna Therapeutics	3/14	-6

When does KYTX report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (tomorrow).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What KYTX reported on Aug 11, 2026

The quarter

The figures are not read from the release yet.

The filing on EDGAR

Where the sales came from

KYTX's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Into 2028
Operating runway	into 2028kept

Figures as filed (SEC filing, Aug 11)

In the company's words

“The Company anticipates sharing longer-term follow-up Phase 2 topline data in Q3 2026.”

From its results filing (SEC filing · Aug 11)

The numbers

Market value: $285M; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on KYTX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-2.9%+5.4%+0.4%

Mar 26May 12Aug 11

Reported	When	Gap	Reaction	5 days
Aug 11, 2026After close	After close	-1.3%	+0.4%	+6.0%
May 12, 2026After close	After close	+0.6%	+5.4%	-15.0%
Mar 26, 2026After close	After close	0.0%	-2.9%	+10.5%

KYTX closed higher after 2 of its last 4 reports.

All 4 reports, and KYTX's Quality Score going into each

Everyone reporting earnings this week

KYTX has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on KYTX, and all 14 on every stock.Get in free →

KYTX RSI today: 39.0, below its 50-day and 200-day averages

Not scored

RSI 39.0, MACD below signal, below both averages. Not scored.13 readings

The deep dive on KYTX

What it does and how it makes money2 findingsFor Pro members2 findings on what KYTX does and how it makes money, for Pro members
Where it stands3 findings3 offerings of shares or notes since Apr 2025, $250M in all.SEC filing · Apr 2, 2026
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades KYTX, for Pro members

5 more findings on KYTX, each with its source, for Pro members.

KYTX share count over time

Shares: 40.9% more than a year ago (to Jun 30).

Shares of KYTX outstanding, as filed
Shares outstanding	As of
61.8M	Aug 3, 2026
60.8M	May 1, 2026
60.4M	Mar 1, 2026
43.8M	Oct 31, 2025

Offerings, shelves, and splits of KYTX, from its filings
From its filings	Filed
Set up an at-the-market program for up to $100M of shares, about 35% of its market value	Apr 2, 2026
Registered shares for a later sale (S-3)	Mar 26, 2026
Raised $100M in a sale of shares, about 35% of its market value	Dec 18, 2025
Set up an at-the-market program for up to $50M of shares, about 18% of its market value	Apr 15, 2025

3 more offerings on file, for Pro members.

KYTX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Warner Weston BiddleChief Executive Officer · no trades on file
Christi ShawExecutive Chairperson · no trades on file
Marc GrassoChief Financial Officer · no trades on file
Karen Marie WalkerChief Technology Officer · 1 trade
Naji GehchanOfficer · no trades on file
Beth C. SeidenbergDirector · 1 trade
Ian T. ClarkDirector · no trades on file
Andrew Craig MillerDirector · no trades on file

3 more officers and directors file at KYTX.

See insider trades by person

Which ETFs hold KYTX?

In ETFs: KYTX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

149 employeesEmeryville, CAkyvernatx.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on KYTX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn KYTX's score around: 8 things
8 more filings explained, a plain line each
5 more things pulling KYTX's score down

See KYTX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: KYTX's Quality Score is -6 (Poor), #235 of 281 in Biotech.

What does KYTX's Quality Score say?

KYTX scores -6 today, which Breakaway calls Poor. It is #235 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 36% in 3 months while the S&P 500 fell 2%. Shares: 40.9% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is KYTX's Quality Score?

KYTX scores -6 today, which Breakaway calls Poor (below zero). That is #235 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KYTX's -6.

When does KYTX report earnings?

Expected to report Wed Nov 11, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. KYTX closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.